The 2012 Update of the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults

By: Shannon Tellier

Medication related problems can be reduced in older adults if the Beers Criteria were utilized by health care professionals. The criteria serves as a guideline to identify potentially inappropriate medications (PIMs) that should be avoided in the elderly population, but it should not replace clinical judgment. This 2012 update includes a systematic literature review, use of an expert panel, grading the strength of evidence, and three categories of PIMs. The categories include PIMs and classes to avoid in older adults, PIMs and classes to avoid in older adults with certain diseases and syndromes that the drugs can exacerbate, and medications to be used in caution in older adults. The 2012 update to the Beers Criteria is necessary due to new medication, recalled medication, and insufficient or new evidence evaluated by the panel.

As pharmacists and pharmacy students, it is important to be aware of classes of medications that have potential to harm older adults. Additions to the 2012 update include megestrol (Megace®), glyburide (DiaBeta®, Glynase®), sliding-scale insulin, thiazolidinediones or glitazones with heart failure, acetylcholinesterase inhibitors with history of syncope, and selective serotonin reuptake inhibitors with falls and fractures. Due to insufficient evidence, new evidence, or removal from the U.S market, nineteen medication and medication classes have been removed from the 2012 update. Some of the dropped medications include propoxyphene and combination products, daily fluoxetine (Paxil ®), and ferrous sulfate >325 mg/day. A combination of clinical judgment and familiarity with the Beers Criteria by all health care professionals will help reduce adverse drug events in older adults.

Read the 2012 Beers Criteria update at: http://onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2012.03923.x/pdf

eMAR

Recent Posts

Oxidative Stress and Its Impact on Vitiligo

By: Zurriya Faran, PharmD Candidate c/o 2031 The visible loss of skin pigmentation often indicates…

2 months ago

Thiamine Metabolic Dysfunction Syndrome: Overview, importance, MOA, and treatment

By: Archana Murugan, PharmD candidate c/o 2029 Overview             Thiamine metabolic dysfunction syndrome (TMDS) refers…

2 months ago

Updated Guidelines for the Treatment of Multidrug and Rifampin-Resistant TB and Promising New Anti-TB Drugs in Phase 2/3 Trials

By: Kevin Lee, PharmD Candidate c/o 2028, Angela Yin, PharmD Candidate c/o 2028             The…

2 months ago

Sixth Year Perspective: Interview with Ariella Zadrima, PharmD Candidate, c/o 2026

By: Aymon Choudhury, PharmD Candidate c/o 2027 APPE questions: How did your APPE rotations shape…

2 months ago

Foundayo: The New Drug in the GLP-1 market

By: Sariah Grant, PharmD Candidate c/o 2027             The rise of glucagon-like peptide -1 receptor…

2 months ago

Should All Drugs be OTC? Risks and Consequences of the FDA Commissioner Statement

By: Amanda Kastel, PharmD Candidate c/o 2027 In February 2026, FDA Commissioner Marty Makary stated…

2 months ago